Bicycle Therapeutics Q1 net loss narrows to $26.6M; cash $457M; Phase 2/3 trial initiated

BICYCLE THERAPEUTICS PLC

2024-Q1 EPS reported -$0.62 revenue$19,530,000

Cash and equivalents $457.0M as of Mar 31, 2024, down from $526.4M at Dec 31, 2023.
Net loss of $26.6M ($0.62 per share) vs $39.1M ($1.30) in Q1 2023; improvement helped by $8.2M retroactive UK R&D tax credits.
R&D expenses rose to $34.9M from $32.2M YoY, driven by BT8009 clinical program costs.
Initiated Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer; enrollment ongoing.
Mike Hannay promoted to Chief Product and Supply Chain Officer; multiple clinical data readouts expected in 2H 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BICYCLE THERAPEUTICS PLC reported first quarter ended March 31, 2024 results: net income Net loss was $26.6 million, EPS $(0.62) basic and diluted net loss per share.

Period: first quarter ended March 31, 2024
Net income: Net loss was $26.6 million
EPS: $(0.62) basic and diluted net loss per share
Result: reported results

Exact text from the filing

Net loss was $26.6 million, or $(0.62) basic and diluted net loss per share, for the three months ended March 31, 2024

View on SEC.gov

1435 earnings releases filed in the last 30 days. Browse all earnings releases →

BICYCLE THERAPEUTICS PLC filing history →

Source: SEC EDGAR

accession 0001104659-24-055981

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.